Clinical trial
Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions
NCT00802828 is registered in ClinicalTrials.gov with Perrigo Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions
- Lead sponsor
- Perrigo Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2004
- Completion date
- Not reported
- Enrollment
- 44 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
bioavailability